Abstract
Extracellular vesicles (EVs) derived from cell membranes act as therapeutics and targeted drug carriers. However, the production scalability and reproducibility of EVs limit their biomedical applications. In the past few years, our lab has developed a nitrogen cavitation approach to efficiently produce EVs from any types of eukaryotic cells and bacteria. We have demonstrated that EVs derived from differentiated HL-60 cells can improve the treatment of inflammatory diseases. In addition, we have showed an increased survival of animals from bacterial infections by Pseudomonas aeruginosa after the mice were immunized with the nanovesicles derived from Pseudomonas aeruginosa membrane.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
